Featured Product: Saltonase, the Versatile Nuclease - Salt Tolerant and Easier Purification
Exhibitor: QIAGEN N.V.
Date: 2024-07-05
Booth No.: L823
During the biopharmaceuticals' production processes, engineered bacteria or cells are commonly used as hosts. Residual nucleic acids from these hosts can pose potential safety risks. For instance, DNA residues from continuously passaged host cells may lead to uncontrolled proliferation in human cells, or causing infections due to nucleic acid residues from integrated viruses in the body. Due to these risks, both the World Health Organization (WHO) and national drug regulatory authorities strictly control the levels and fragment lengths of nucleic acids in residual hosts. Typically, residual DNA in vaccines and other biologics is controlled to 100pg/dose, with allows up to 10ng/dose in special circumstances, and residual DNA fragments must be less than 200 base pairs [1]. Saltonase, as a versatile nuclease, offers an effective solution for removing host nucleic acid contamination. However, during virus purification processes, host-cell DNA is highly condensed and wrapped around histones and other nucleoproteins. These processes lead to chromatin formation, which primarily leads to the following issues:
- Protects genomic DNA (gDNA) from degradation
- Frequently binds to chromatography media (i.e. anion-, cation-exchange, HIC and affinity resins) than the products they are intended to purify
- Causes resin and filtration membrane fouling in chromatography
- Aggregates viral vectors which reduces yield during purification processes and may adversely affect vector transfection efficiency, biodistribution, and immunogenicity following in vivo administration
Higher salt conditions can effectively address these issues. High ionic strength enables nucleic acids to dissociate from targeted proteins and become accessible for efficient nucleolytic digestion. Also, it reduces product viral vector aggregation, inhibits the activity of many proteases’ and ultimately increases purification yield. Besides that, higher salt conditions are preferred in many chromatographic steps during the purification process like reducing non-specific interaction with resin, improving target binding, prevent fouling.
The method to remove nucleic acid contamination in high-salt buffer solutions remains a challenge. At higher salt concentrations, enzymatic activity from traditional nucleases are hard to maintain, posing challenges for both purification processes and costs. BLIRT (Gdańsk), a leading enzyme manufacturer in Europe acquired by QIAGEN, has developed the versatile nuclease known as Saltonase which ensures high activity across a wide range of salt concentrations (0.1 – 1.1 M NaCl), effectively degrading nucleic acids to below 10 base pairs.
Figure 1: Comparison of saltonase with market leaders in activity over a broad range of salt concentrations
Saltonase exhibits higher tolerance to varying concentrations of Na+ while other market leaders lose activity tolerance beyond salt concentrations of >250 mM.
Figure 2: Saltonase is active in a wider range of salt environment (0.1 – 1.1 M NaCl)
In conclusion, Saltonase demonstrates broad applicability across a wide range of temperatures (15–55°C), pH levels (6.8–9.3), buffers, and additives while maintaining higher activity. It is highly versatile, easy to be deactivated during production and has excellent purification and quality control process which fundamentally address instability issues. From a long-term and cost perspective, it serves as an effective solution for removing host nucleic acids in biopharmaceutical production!
Order information
[1] Luyao Yan. Research progress on detection of host cell residual DNA in biological products. International Journal of Biologicals, 2021, 44(3):5. DOI:10.3760/cma.j.cn311962-20200409-00039.
Promotional video - OEM by QIAGEN: Strategic Partnerships
More Exhibitor's Press Release
- Taiwan’s Regenerative Medicine Acts passed, MYCENAX CDMO Services Are Ready! MYCENAX BIOTECH INC. / 2024-07-08
- Registration Today! 2024 BIO Asia Taiwan. Golden Biotech Seminar Registration GOLDEN BIOTECHNOLOGY CORP. / 2024-07-06
- EffPha meets you at BIO Asia- Taiwan Exhibition 2024 EFFICIENT PHARMA MANAGEMENT CORP. / 2024-07-05
- EffPha – An expert-based CRO for your drug development EFFICIENT PHARMA MANAGEMENT CORP. / 2024-07-05
- Vega Preclinical Ultrasound System J & H TECHNOLOGY CO., LTD. / 2024-07-05
- MYCENAX,YOUR BEST PARTNER FOR BIOLOGICS DEVELOPMENT MYCENAX BIOTECH INC. / 2024-07-04
- Bora Expands North American Footprint with Agreement to Acquire First Sterile Manufacturing Facility BORA PHARMACEUTICALS CO., LTD. / 2024-07-03
- Application and Market Development of Foods with Functional Claims in Japan GREENLINK BIOTECH INC. / 2024-07-03
- Featured Product: QIAGEN Beverly Single-Tube Enzymatic Fragmentation Library Preparation QIAGEN N.V. / 2024-07-02
- OEM by QIAGEN: Strategic Partnerships – A Partner that Extends Your Capabilities QIAGEN N.V. / 2024-07-02
- Comparison of Maglev Centrifugal Pump and Quaternary Diaphragm Pump Effects on mRNA encapsulated LNP LEVITRONIX GMBH TAIWAN BRANCH / 2024-07-01
- CRISPR cGMP gRNA Manufacturing MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- High-Throughput NGS Assistant - Feyond-F100 Fluorescence Microplate Reader MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- CLUBIO Life science solutions help universities upgrade equipments MEDCLUB SCIENTIFIC CO., LTD. / 2024-06-27
- EDA providing the most advanced and innovative optoelectronic medical equipment. EDA MEDICAL DEVICES TECHNOLOGY INC. / 2024-06-25
- TaiMed Biologics: Comprehensive CDMO Services from Bench to Market TAIMED BIOLOGICS INC. / 2024-06-25
- Marker X Decodes the Cancer Proteome Breaking the Limits of Early Cancer Screening Globally! MARKER EXPLORATION CORP. / 2024-06-21
- EffPha is the leading CRO for early phase oncology trials EFFICIENT PHARMA MANAGEMENT CORP. / 2024-06-20
- FUJIFILM Toyama Chemical and Synplogen Enter Strategic Business Alliance Agreement on CDMO Services FUJIFILM CORPORATION / 2024-06-18
- TriLink BioTechnologies® and FUJIFILM Toyama Chemical Sign Non-exclusive License FUJIFILM CORPORATION / 2024-06-18